The MitraClip system achieved an 86.7% acute procedural success rate and 0% major adverse events at 30 days in Japanese patients with chronic mitral regurgitation at high surgical risk.
Observational (n=30)
Yes
Does MitraClip treatment improve MR severity and symptoms in Japanese patients with chronic MR at high risk for surgery?
MitraClip treatment in a Japanese cohort of high-surgical-risk patients with chronic MR resulted in high procedural success, no major adverse events, and significant improvements in MR severity and NYHA class at 30 days.
BACKGROUND: system is a transcatheter-based therapeutic option for patients with chronic mitral regurgitation (MR) who are at high risk for surgery. A prospective, multicenter, single-arm study was initiated to confirm the transferability of this system to Japan. METHODS AND RESULTS: . At baseline, all patients had MR 3+/4+ with 53%/47% patients with degenerative/functional etiology with mean LVEF of 50.2±12.8%, and 37% of patients were NYHA class III/IV. APS was achieved in 86.7% with no occurrence of MAE. At 30 days, 86.7% of patients had MR ≤2+ and 96.7% were NYHA class I/II. CONCLUSIONS: procedure resulted in clinically meaningful improvements in MR severity, function and quality of life measures, and low MAE rates. These early results suggest the transferability of this therapy to appropriately selected Japanese patients. (Trial Registration: clinicaltrials.gov Identifier NCT02520310.).
Hayashida et al. (Sun,) conducted a observational in Chronic mitral regurgitation (n=30). MitraClip was evaluated on Acute procedural success (successful implantation with MR severity ≤2+ at discharge). The MitraClip system achieved an 86.7% acute procedural success rate and 0% major adverse events at 30 days in Japanese patients with chronic mitral regurgitation at high surgical risk.